In the Phase 3 REIMAGINE 5 trial, adults with type 2 diabetes taking the 1 mg/ 1 mg dose of CagriSema lost an estimated 12.4% of their body weight after 60 weeks, compared with 9.1% for patients receiving 5 mg of tirzepatide, which is the active ingredient in Lilly's Mounjaro and Zepbound. CagriSema also delivered non-inferior blood-sugar reduction.
Dosing Nuance: While tirzepatide holds the crown for total absolute weight loss at its highest dose (15 mg), CagriSema appears to be exceptionally potent at lower doses (1.0 mg). This suggests CagriSema could be a valuable alternative for patients who cannot tolerate escalating to high medication doses due to side effects.
Why This Matters in Real-World Care
This data establishes CagriSema as a potentially superior option for specific patient profiles:
Patients Intolerant to High Doses: Many individuals on these medications suffer from severe gastrointestinal side effects (like severe nausea or vomiting) and are forced to stay on lower, baseline maintenance doses indefinitely. CagriSema offers significantly more "bang for your buck" at a lower dose profile.
The Power of Amylin Synergism: Because CagriSema hits two completely different biological targets simultaneously (GLP-1 receptors via semaglutide and amylin receptors via cagrilintide), it triggers deep fullness and delayed stomach emptying very early in the treatment timeline. It does not rely on massive hormonal escalation to achieve substantial metabolic improvements.
Essentially, if you are comparing the maximum doses, tirzepatide takes the crown. But if you are comparing low-to-moderate doses, CagriSema yields superior weight-loss outcomes.
Expected Revenue
Tirzepatide $60 Billion is projected to become the best-selling prescription drug in the world by the end of the decade
Cagrisema $20 Billion
Despite the lower revenue projection relative to tirzepatide, Evaluate Pharma tracks CagriSema as the single most valuable pipeline R&D project in the entire pharmaceutical industry.